Management Team

IR Nav

Robert Davidson

CEO and Chairman of the Board of Directors [-]

Robert Davidson is CURE’s CEO and Chairman of the Board of
Directors. Prior to his role at CURE Pharmaceutical, Robert
Davidson served as President and Chief Executive Officer of InnoZen Inc.,
Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio
Delivery Technologies Inc., and has served on multiple corporate boards.
Mr. Davidson was responsible for the development of several drug delivery
technologies and commercial brand extensions. He has worked with
brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a
private label electrolyte oral thin film sold in major drug store chains.
Mr. Davidson received his B.S. degree with a concentration in Biological Life
Sciences. He has a Masters Certificate in Applied Project Management
from Villanova University, Masters of Public Health from American Military
University, Virginia and a Masters in Health and Wellness from Liberty
University, Virginia. Davidson also completed his Post Graduate Studies at the
University of Cambridge with letter of commendation.

Edward Maliski, PhD

President and Chief Science Officer [-]

Dr. Edward Maliski is CURE’s President and Chief Science Office. Mailski
is an accomplished research scientist with 30 years of experience in the
development of pharmaceutical and biotechnology products. As an
executive leader and strategist, Maliski contributed his expertise in project
management and chemical research to facilitate the transfer of new
discoveries into pharmaceutical products for the Sterling Winthrop
Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc.
Additionally, Dr. Maliski has worked with several successful start-up
companies.

Mark Udell

Chief Financial Officer [-]

Mark Udell is CURE’s Chief Financial Officer, Treasurer and Secretary. As CFO, Mr. Udell is responsible for all strategic tactical matters as they relate to budget management, cost benefit analysis, forecasting need, securing of new funding and overseeing the management and coordination of all fiscal reporting activities for the organization. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to joining CURE Pharmaceutical in 2011, Mr. Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller and was responsible for establishing, monitoring and enforcing policies and procedures for the company as well as conducting audits and working with external auditors. While working at CURE and InnoZen, Inc., Mr. Udell gained valuable knowledge in the drug delivery industry and is a key contributor in the development and commercialization of various drug delivery technologies. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

Jessica Rousset

Chief Operating Officer [-]

Jessica Rousset is CURE’s Chief Operating Officer. Mrs. Rousset oversees operations and drives corporate strategy and growth. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. Mrs. Rousset previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Mrs. Rousset held positions at The Scripps Research Institute and GlaxoSmithkline Biologicals in laboratory, clinical research and business development roles. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.
IR website by IR WebKit